Nyxoah Sa (BE:NYXH) has released an update.
Nyxoah SA has announced successful results from its DREAM U.S. pivotal study, reporting significant improvements in treating Obstructive Sleep Apnea (OSA). The study met its primary endpoints with over 63% of participants showing a positive response to the Genio hypoglossal nerve stimulation system. These results are a step forward for Nyxoah, potentially revolutionizing OSA treatment and setting the stage for FDA approval and U.S. market entry.
For further insights into BE:NYXH stock, check out TipRanks’ Stock Analysis page.
